## BMY: Bristol-Myers Squibb Company - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -0.3% below STRENGTH zone (3.0-6.0%); PEG 2.26 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.0% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($52.35)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Bristol Myers Squibb (BMY) Stock: Weekend News, Analyst Targets, Dividend Update, and What to Watch Before Monday’s Open**
- Source: ts2.tech | 20251228T202814 | Neutral | Relevance: 100%
- Bristol Myers Squibb (BMY) stock ended the week at $54.64, with investors weighing the company's defensive profile and dividend appeal against upcoming patent expirations. Recent news includes institutional activity, mixed analyst targets averaging around $53.93-$59.50, and key pipeline developments for Opdivo and neuroscience programs. The company also announced a 1.6% dividend increase and investors are watching policy implications, especially regarding the Eliquis agreement with the U.S. government, as they head into Monday's trading session and Q4 2025 earnings in February 2026.

**2. Bristol-Myers Squibb (BMY) Stock: What Investors Should Watch Before Monday’s Open as Dividend Date, Earnings, and 2026 Catalysts Come Into Focus**
- Source: ts2.tech | 20251227T225136 | Somewhat-Bullish | Relevance: 100%
- Bristol-Myers Squibb (NYSE: BMY) is heading into the end of 2025 with investor attention on its dividend timeline, upcoming earnings, and key 2026 regulatory and pipeline milestones. The stock finished Friday at about $54.65, with analysts holding mixed views and a consensus "Hold" rating. Investors should particularly watch the dividend record date of January 2, 2026, the Q4 2025 earnings report expected on February 5, 2026, and a PDUFA goal date of April 8, 2026, for Opdivo.

**3. Bristol-Myers Squibb (BMY) Stock: Weekend Market Close, Fresh Institutional Filings, and What to Watch Before Monday’s Open**
- Source: ts2.tech | 20251227T204532 | Neutral | Relevance: 100%
- Bristol-Myers Squibb (BMY) stock is heading into the weekend with U.S. equity markets closed, after essentially flat trading typical of late-December. Investors are reviewing fresh institutional ownership updates, with several firms adjusting their positions, and monitoring catalysts like the upcoming dividend payment and the evolving U.S. drug pricing environment. The company's Q4 2025 results are scheduled for February 5, 2026, which will be the next major scheduled catalyst for the stock currently trading within a range, balanced between income appeal and longer-term growth questions.

**4. JP Morgan 2026 Preview: Bristol Myers Squibb’s Continued Growth**
- Source: Pharmaceutical Executive | 20251224T142812 | Bullish | Relevance: 100%
- Bristol Myers Squibb (BMS) is focusing on a diversified portfolio and pipeline execution in oncology, cardiovascular, and neuroscience to drive sustained growth post-loss-of-exclusivity. The company's strategy involves incremental growth across multiple assets and therapeutic areas rather than relying on a single blockbuster. 2024 and 2025 were characterized by groundwork laying, cost discipline, and acquisition integration, setting the stage for more consistent growth in 2026 and beyond.

**5. Meyer Handelman Co. Sells 52,438 Shares of Bristol Myers Squibb Company $BMY**
- Source: MarketBeat | 20251227T124046 | Somewhat-Bullish | Relevance: 100%
- Meyer Handelman Co. reduced its stake in Bristol Myers Squibb Company by 9.9%, selling 52,438 shares and retaining 475,518 shares valued at approximately $21.45 million. This occurred as Bristol Myers Squibb reported strong quarterly earnings, beating expectations with $1.63 EPS and $12.22 billion revenue, and increased its quarterly dividend to $0.63. The company also provided a positive FY2025 EPS guidance, while institutional investors collectively own 76.41% of the stock.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 5, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | B of A Securiti | $61 | $52 | +17% |
| 2025-12-12 | Morgan Stanley | $37 | $36 | +3% |
| 2025-12-12 | Guggenheim | $62 | $0 | 0% |
| 2025-12-10 | Wells Fargo | $55 | $53 | +4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | B of A Securiti | up | Buy |
| 2025-12-12 | Morgan Stanley | main | Underweight |
| 2025-12-12 | Guggenheim | up | Buy |
| 2025-12-10 | Wells Fargo | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 7 ($0.00M) |
| Sells | 3 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 41.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.6% (+0.5%)
- Blackrock Inc.: 8.6% (+1.9%)
- JPMORGAN CHASE & CO: 8.5% (+65.8%)
- State Street Corpora: 4.7% (+2.0%)
- Charles Schwab Inves: 3.6% (+3.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 5 raises (avg +11%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.26 elevated, pricing in significant growth expectations. Quality metrics strong (ROE 34%). Balance sheet: $6.0B free cash flow. Revenue declining -8% YoY, concerning. Analyst sentiment positive (5 raises, avg +11%). Institutional flow bullish (7 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $111.2B |
| Beta | 0.30 |
| 52W Range | $42.52 - $63.33 |
| Short Interest | 1.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.26 |
| Forward P/E | 9.1 |
| Current P/E | 8.4 |
| YoY Growth | -8.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 2.7% to -0.3% (-3.0% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.3pp (needs >3.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: -DBL (Indecision).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.27% (CS: 67) | Neutral |
| RSI_14 | 69.4 | Neutral |
| MACD Histogram | 0.06 | Bullish |
| vs SMA20 | 1.045x | Above |
| vs SMA50 | 1.128x | Above |
| vs SMA200 | 1.124x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $54.67
- **Stop Loss:** $52.35 (4.2% risk)
- **Target:** $56.99 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 568
- **Position Value:** $31,052.56
- **Portfolio %:** 31.05%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite amid holiday trading. VIX at extreme lows (13.6) signals complacency while positive yield curve (+59bps) and stable economic data support continuation. Focus on quality names with AI/infrastructure exposure while monitoring January volatility reset.*

### Earnings

**Next:** 2026-02-05 (Est: $1.65)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.52 | $1.63 | +7.6% |
| 2025Q2 | $1.10 | $1.46 | +32.6% |
| 2025Q1 | $1.50 | $1.80 | +19.9% |
| 2024Q4 | $1.47 | $1.67 | +13.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*